SANDOZ INC

Lobbying for SANDOZ INC · Pharmaceutical company

Filing 2nd Quarter - Report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$170,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New Jersey

Official filing document

Government bodies contacted 6

Commerce, Dept of (DOC)
Defense, Dept of (DOD)
Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 1

Medicare/Medicaid

Policies related to the ASP calculation in Medicare Part B Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.